Creo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Creo Medical develops minimally invasive electrosurgical devices designed to improve patient outcomes. With its innovative CROMA and Kamaptive technologies, Creo Medical is setting new standards in precision and flexibility for clinicians across a range of surgical procedures. This funding has been sought to mitigate the completion risk of its recently announced sale of a 51% controlling interest in the group’s European subsidiary, Creo Medical Europe. It also aims to provide balance sheet strength for future growth, as Creo Medical continues to roll out its defined medtech strategy.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, served as advisor to Creo Medical on the transaction.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreBackspin has completed a mandatory public tender offer for the shares of Spindox
Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn more